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Amyotrophic lateral sclerosis (ALS) is characterized by progressive
degeneration of motor neurons leading to muscle paralysis.
Research in transgenic mice suggests that the muscle actively
contributes to the disease onset, but such studies are difficult to
pursue in humans and in vitro models would represent a good
starting point. In this work we show that tiny amounts of muscle
from ALS or from control denervated muscle, obtained by needle
biopsy, are amenable to functional characterization by two differ-
ent technical approaches: “microtransplantation” of muscle mem-
branes into Xenopus oocytes and culture of myogenic satellite
cells. Acetylcholine (ACh)-evoked currents and unitary events were
characterized in oocytes and multinucleated myotubes. We found
that ALS acetylcholine receptors (AChRs) retain their native phys-
iological characteristics, being activated by ACh and nicotine
and blocked by α-bungarotoxin (α-BuTX), d-tubocurarine (dTC), and
galantamine. The reversal potential of ACh-evoked currents and
the unitary channel behavior were also typical of normal muscle
AChRs. Interestingly, in oocytes injected with muscle membranes
derived from ALS patients, the AChRs showed a significant de-
crease in ACh affinity, compared with denervated controls. Finally,
riluzole, the only drug currently used against ALS, reduced, in
a dose-dependent manner, the ACh-evoked currents, indicating
that its action remains to be fully characterized. The two methods
described here will be important tools for elucidating the role of
muscle in ALS pathogenesis and for developing drugs to counter
the effects of this disease.
voltage-clamp | patch-clamp
Amyotrophic lateral sclerosis (ALS) is a rare but fatal diseasecaused by a progressive degeneration of motor neurons that
occurs sporadically in over 90% of the patients. Except for a
minority of genetic causes, the etiology of the disease is still
unknown, but there is a general consensus that multiple mech-
anisms combine to cause the pathology (1). To date, no effective
treatment exists, although the lifespan of ALS patients can be
slightly increased by riluzole, the only drug approved for treat-
ment of ALS (2).
The hallmark of the pathology is the selective death of upper
and/or lower motor neurons, but several researchers point out that
muscle denervation precedes neuronal death in mouse models of
the pathology, according to the so-called “dying back” model of
neuronal death (3, 4). It has been proposed that muscle actively
contributes to motor neuron degeneration, possibly by releasing
factors that inhibit neurite outgrowth (5, 6). Endplate acetylcholine
receptors (AChRs) might also play a role in the disease, as their
silencing mimics axotomy by increasing the excitability of motor
neurons in wild-type mice (7). However, these hypotheses are
largely based on data obtained in transgenic mice expressing var-
ious mutant forms of the human SOD1 enzyme, which in humans
accounts for a minority of cases; only one case of human disease
has been evaluated in this regard (8).Whether taking place early or
late in disease, muscle denervation is an inescapable feature of
ALS and, among other effects, it has a deep impact on AChR
composition and distribution. In normally innervatedmuscle fibers,
AChRs are composed of α1-, β1-, ε-, and δ-subunits (ε-AChR) and
are clustered at high density at the nerve–muscle and muscle–
tendon junctions (9–11).
Upon denervation, ACh supersensitivity occurs: extrasynaptic
nuclei resume transcription of AChR subunit genes, and recep-
tors containing α1, β1, γ, and δ (γ-AChRs) appear over the entire
sarcolemma (12–14). The AChR isoforms differ in conductance
and kinetics, as well as in ion selectivity, both in rodents and
humans (15, 16). Riluzole produces a slight reduction in the ACh-
evoked currents in cells expressing recombinant mouse ε-AChRs
(17), although only if used at high, nonclinical concentrations (2),
raising concerns about possible side effects on neuromuscular
transmission. All these open questions make it clear that new
experimental systems allowing a detailed investigation of muscle
abnormalities in human cases of ALS may provide insight into the
pathogenesis and treatment of the disease.
In this work we took advantage of the oocyte microtrans-
plantation technique (18, 19) to study the function of muscle
AChRs of ALS patients. This approach allows the exploitation of
tiny muscle fragments obtained by needle biopsies, thus mini-
mizing the patient’s discomfort. In parallel experiments, some
muscle fragments were cultured to derive satellite cells and hence
polynucleated myotubes, from which ACh-evoked whole-cell and
unitary currents were recorded despite the limited differentiative
capability of satellite cells from ALS patients (20). In these two
preparations we tested the effects of riluzole and other drugs
considered potentially useful therapeutic tools for ALS. The
results obtained indicate that both experimental systems have the
potential to become highly valuable for investigation of the role of
muscle in the onset and progression of sporadic ALS, as well as to
test the direct and possibly unwanted side effects of any drug
proposed as a therapeutic agent for ALS.
Results
Functional Expression of Native AChRs from Human Muscles in
Xenopus Oocytes. Injections of Xenopus oocytes with membranes
extracted from muscle specimens of 13 of the 19 ALS patients (P)
studied (P1–12 and P17 in Table S1) and 8 of 9 denervated control
patients (P20–22 and P24–28) (Table S1) led to the incorporation
of functional AChRs into the oocyte membrane. Application of
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ACh to these cells (5 μMto 1mM; Figs. 1 and 2) elicited an inward
current, the peak amplitude of which depended on transmitter
concentration, whereas noninjected oocytes showed no detectable
responses to ACh. Muscle membranes microtransplanted from a
few patients (P13, 16, 18, 19, and 23) did not elicit detectable
responses to ACh, probably due to the small number of functional
AChRs incorporated into the oocyte plasma membrane.
In oocytes injected with muscle membranes from ALS patients,
ACh (100 μM at −60 mV) elicited a current (IACh) with mean
peak amplitude of −16.4 ± 2.4 nA [mean ± SEM; 123 oocytes/28
frogs (123/28); range, −5 to −31 nA, Fig. 1A]. Currents of similar
amplitude were recorded from oocytes injected with muscle
membranes from denervated control patients (−14.2± 5 nA; 66/2;
range, −4 to −30 nA, Fig. 1A). Those currents were caused by
activation of transplanted functional AChRs because they were
blocked by the classical antagonists of nicotinic AChRs, α-bun-
garotoxin (αBuTX) (5 μM, 30 min of pretreatment; 10/2; P1, P5,
P20, and P21, Fig.1A) and d-tubocurarine (dTC) (10 μM, 2 min of
pretreatment; 15/3; P1, P5, and P20; Fig. 1A). Moreover, the
currents were activated by nicotine (0.5 or 1 mM, Fig. 1B), con-
sistent with the effects of antagonists on activation of nicotinic
AChRs derived from the injected membranes.
Functional Characteristics of AChRs from Human Muscles. Experi-
ments were aimed at comparing the functional characteristics of
IACh in oocytes injected with membranes from the two groups of
patients (Table S1), selecting the membrane preparations that
produced the largest ACh-evoked responses. We first analyzed
AChR desensitization in oocytes injected with muscle membranes
obtained from ALS or denervated patients. During prolonged
applications of ACh (250 μMfor 2min), IACh showed a decay (Fig.
1C) that was adequately fitted by a single exponential function.
The decay time constants were similar in oocytes injected with
membranes from ALS (τdecay = 9.8± 0.7 s, 15/3; P1 and P5) or
denervated patients (τdecay = 8.9 ± 0.3 s, 15/3; P20 and P21; P >
0.05). We also measured current decays during repetitive ACh
applications (100 μM, 5-s duration, 40-s interval). In oocytes
injected with ALS muscle membranes (P1, P4, P9, and P10) the
peak amplitude of the 10th IACh was 53 ± 6% (10/3) of the first,
comparable to that observed in oocytes injected with denervated
muscle membranes (55 ± 5%, 10/3 frogs; P20, P21, and P25,),
showing that AChR desensitization is similar in muscles of ALS or
denervated patients under the experimental conditions used here.
The ACh dose–current response relation in oocytes injected
with membranes from five denervated patients (P20–22, P24, and
P25; Fig. 2A) yielded half-maximal effect (EC50) and nH values of
33 ± 3 μM and 1.4 ± 0.1, respectively (28/3). In oocytes injected
with membranes isolated from ALS muscles (P1, P4–6, P8; Fig.
2A) the EC50 was significantly greater (56 ± 3 μM, 28/3; P < 0.05),
whereas nH was unchanged (1.4 ± 0.1). The current–voltage re-
lation showed slight inward rectification for both groups of
patients (Fig. 2B) and the reversal potential for IACh was similar in
oocytes injected withALS (−5.1± 0.2 mV; 10/3 ; P1, P5, and P9) or
denervated muscle membranes (−4.4 ± 0.2 mV, 8/3; P20 and P21).
A
B
C
Fig. 1. Nicotinic AChRs are incorporated by oocytes injected with muscle
membranes from ALS or denervated patients. (A, Left). Superimposed cur-
rents elicited by 100 μM ACh before and after pretreatment with 5 μM
αBuTX in 1 oocyte, representative of 10, microinjected with muscle mem-
branes from one ALS patient (P1). (Right) Sample traces elicited by 100 μM
ACh before and after 10 μM dTC in 1 oocyte, representative of 15, injected
with muscle membranes from the same patient. In this and subsequent
figures, horizontal filled bars indicate the timing of ACh applications and
open bars that of drug applications. Holding potential was −60 mV. Note the
complete block of ACh-evoked currents after αBuTX or dTC. (B) Typical
currents evoked by nicotine (500 μM, open bars) in 2 oocytes, representative
of 10, injected with muscle membranes from one ALS (P1; Left) and one
denervated patient (P20; Right). (C) The current decay during prolonged
ACh applications (250 μM for 2 min) is similar in oocytes injected with muscle
membranes from one ALS (P5; Left) and one denervated patient (P21; Right).
Experiments are representative of 15 oocytes.
Fig. 2. Characterization of ACh-evoked currents in injected oocytes. (A) Amplitude of currents evoked by various ACh concentrations, expressed as percentage
of the maximal current evoked by 1 mM ACh, plotted as mean ± SEM and best fitted with Hill curves. Averaged EC50 values and nH in oocytes injected with
membranes from denervated patients were 33 ± 3 μM and 1.4 ± 0.1 (●; 28 oocytes/3 frogs; five patients); for ALS patients values were 56 ± 2.6 μM and 1.4 ± 0.1
(○; 28/3; five patients). (Inset) Currents elicited by the indicated ACh concentrations (in μM) in oocytes injectedwith ALS (Right) or denervatedmembranes (Left)
as indicated. (B) ACh current–voltage relation in oocytes injected with denervated (●, 8/3; two patients) or ALS muscle membranes (○, 10/3; three patients). In
each cell, the peak amplitudes of ACh-evoked (100 μM) currents were normalized to that evoked at −60 mV. Reversal potentials of IACh were −4.4 ± 0.2 mV (●)
and −5.1 ± 0.2 mV (○). (Inset) Sample traces of IACh elicited at the holding potentials indicated (mV) in 1 oocyte injected with ALS membranes.
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Functional Effects of Drugs Used in ALS Therapy on Human Muscle
AChRs. Riluzole blocks mouse nicotinic AChR in transfected
HEK-293 cells (17) and membrane-injected oocytes represent an
ideal preparation for testing the effect of riluzole on AChRs
derived from muscles of ALS patients (Fig. 3). In 12 oocytes
injected with membranes from ALS patients (P1 and P5), cur-
rents evoked by ACh (100 μM) were blocked by riluzole (coap-
plied with ACh after a 20-s pretreatment) with half-inhibitory
concentration (IC50) of 22.3 ± 5 μM and nH = 1.0 ± 0.2. Similar
values of IC50 and nH (23.8 ± 5 μM and 1.0 ± 0.1; 12/2) were
obtained in oocytes injected with membranes from denervated
patients (P20 and P21; Fig. 3).
Because riluzole plasma concentration in ALS patients is in
a range of 0.5 to 5 μM (2), we performed additional experiments
using riluzole at a clinically relevant concentration (0.5 μM),
increasing the duration of pretreatment to 2 min. With this ap-
plication protocol, riluzole caused the IACh to decrease to 71 ±
7% (8/2) and 72 ± 9% (8/2) in oocytes injected with muscle
membranes from ALS (P1 and P5) and denervated patients (P20
and P21), respectively. The block was completely reversible after
4 min of washout.
To exploit further the potential of our experimental prepara-
tion, we studied the effects of galantamine and erythropoietin
(Epo), two drugs that have been proposed as therapeutics for
ALS and that could affect the function of muscle AChR. Gal-
antamine is an acetylcholinesterase inhibitor used for Alz-
heimer’s disease; at low concentrations it can weakly activate
muscle AChRs, whereas it acts as an open channel blocker at
higher concentrations (21, 22). In oocytes injected with ALS
membranes (P1 and P9; 9/2 oocytes) galantamine failed to evoke
currents but blocked currents evoked by ACh (250 μM) in
a dose-dependent manner (10–500 μM, 30-s pretreatment; 20/3;
Fig. 4A). As for many open-channel blockers, galantamine-in-
duced block of IACh was fully reversible and voltage dependent.
For example, application of 500 μM galantamine reduced IACh
amplitude to 16 ± 2% of control at −100 mV and to 79 ± 4% at
−20 mV (8/2; P < 0.05). In contrast to galantamine, Epo (5–10
units/mL), which has recently been suggested as a new drug for
ALS because of its neuroprotective properties (23), had no sig-
nificant effect on the IACh amplitude or decay in these oocytes
(15/3; e.g., Fig. 4B; P1 and P9).
Patch-Clamp Recordings on Myotubes from ALS Patients.We derived
polynucleated myotubes from ALS and denervated muscles and
studied their AChR channels using patch-clamp recordings.
Cultures derived from either denervated or ALS patients con-
tained comparable percentages of myogenic, desmin+ cells (14 ±
3%, n = 4 vs. 14 ± 2%, n = 8) and yielded myotubes of equiv-
alent size, as revealed by similar fusion index (62 ± 1%, n = 4 vs.
43 ± 1%, n= 8; P > 0.05) and membrane capacitance (80.2 ± 5.9
pF, n = 30 vs. 78.1 ± 6.5 pF, n = 41; P > 0.05). ACh concen-
tration–current response curves were similar in the two sets of
cells, as was the density of ACh-evoked whole cell currents (Fig.
5 A and B). At a concentration of 100 μM, ACh evoked currents
decayed exponentially, with time constants (τdecay) of 156 ± 11
ms (n= 30) or 150 ± 10 ms (n= 41) for myotubes obtained from
denervated and ALS patients, respectively (Fig. 5A). Riluzole
reduced the amplitude and accelerated the decay of ACh-evoked
currents in all myotubes tested. When a clinically relevant con-
centration of riluzole (0.5 μM) was applied 30 s before coap-
plication with ACh (100 μM), current amplitude was decreased
to 67 ± 4% (n = 13) and τdecay to 63 ± 3% of the control values
measured in the same myotubes from denervated patients. In
ALS myotubes, amplitude and τdecay were reduced to 60 ± 4%
and 69 ± 2% (n = 15), respectively (Fig. 5A).
When cells were bathed in normal extracellular saline (NES),
ACh-evoked unitary events were recorded in 60% of patched
myotubes obtained from denervated patients but only in 20% of
the ALS myotubes (Fig. 5C), largely because seals were unstable
in the latter preparation. Most experiments were therefore per-
formed on myotubes bathed in a KCl-based extracellular solu-
tion, with NES plus ACh (0.1 μM) in the patch pipette. Channel
slope conductance was 35.3 ± 1.8 pS (n = 9) in myotubes from
denervated patients and 36.9 ± 1.3 pS (n = 10) for ALS myo-
tubes. In all cases, the distribution of channel open duration was
adequately fitted by two exponential components with similar
time constants (e.g., Fig. 5C). Channel closed duration showed
large patch-to-patch variations, likely reflecting the number of
channels within each patch.
Discussion
In this paper we present proof of principle that muscle specimens
donated by ALS or denervated patients through minimally in-
vasive procedures can be used for microtransplantation of AChRs
by membrane injection into Xenopus oocytes (18, 19) and for
generating polynucleated myotubes from muscle satellite cells.
Both experimental preparations allow detailed functional studies
of AChR channels and other muscle ion channels. These methods
will be valuable in testing the currently emerging hypothesis that
the neuromuscular junction represents the site of disease onset
Fig. 3. Inhibition of ACh-evoked currents by riluzole in oocytes injected with
muscle membranes from denervated (●, 12 oocytes/2 frogs; two patients) or
ALS patients (○, 12/2; two patients). The amplitudes of currents evoked by
ACh (100 μM, −60 mV) plus riluzole are expressed as percentage of control
currents (ACh alone). IC50 and nH were 23.8 ± 5 μM and 1.0 ± 0.1 (●); 22.3 ±
5 μM and 1.0 ± 0.2 (○). The sample traces represent currents elicited by ACh
(100 μM) alone or in the presence of riluzole (20μM, open bar) in two oocytes,
injected with ALS or denervated membranes, as indicated.
//
//
A
B
Fig. 4. (A) Sample current traces elicited by 250 μM ACh before and after
treatment with 500 μM galantamine (open bar) in 1 oocyte (representative
of 20) injected with ALS muscle membranes (P9, Table S1). (B) Current traces
elicited by 100 μM ACh before and after treatment with 10 units/mL Epo
(open bar) in 1 oocyte (representative of 15) injected with ALS muscle
membranes (P9, Table S1).
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and that skeletal muscle directly contributes to ALS pathogenesis
(1, 4, 5), the so-called “dying-back model.”
Microtransplantation of muscle-type AChR has been achieved
before (24, 25); here we demonstrate the feasibility of this pro-
cedure when starting from tiny muscle samples, indicating that
this approach is efficacious for studies of AChRs in human
muscle diseases. Cultured myotubes from needle biopsies have
also been obtained by others (26), but to our knowledge this is a
unique study performing functional studies on myotubes derived
from patients with a disease reported to reduce the differ-
entiative capacity of the satellite cells (20).
The action of nicotine, the current–voltage relationship, and
the effects of classical nicotinic antagonists indicate that the
ACh-evoked currents measured in muscle membrane-injected
oocytes are due to the activation of bona fide nicotinic AChRs
derived from the patients’ muscles. A modest rectification in
current–voltage relation for human muscle γ-AChR channels has
been previously observed in native preparations (27, 28).
No difference was found when comparing the functional
properties of AChRs in myotubes derived from the two groups of
patients, matching previous reports for human myotubes derived
from healthy subjects (28) and for reconstituted γ-AChR chan-
nels (16). These data suggest that satellite cells from ALS
patients, when exposed to the standardized culture medium, yield
myotubes expressing “normal” γ-AChR, as expected from their
developmental program. ACh-evoked currents of oocytes injec-
ted with muscle membranes from ALS or denervated patients
showed an almost identical pattern of AChR desensitization, in-
dicating that this receptor property is not altered in ALS patients.
Conversely, there was a small but significant difference in ACh
sensitivity. The larger EC50 observed for ALS AChRs in injected
oocytes could be due to a variable proportion of γ- and ε-AChRs
in the muscle membranes derived from ALS patients, reflecting
the cycles of denervation/reinnervation typical of ALS. Values
reported for human γ- or ε-AChR (29, 30) are in the same range,
as the EC50 we report for AChR from denervated patients.
Whereas it is clear that humanmyotubes fromALS or denervated
patients express the fetal form of the AChR, our biopsied muscle
tissues from ALS patients transplanted in oocytes may express
mixed γ/ε-containing receptors. Further experiments using quanti-
tative RT-PCR or immunostaining procedures will provide tests
of this hypothesis. However, because the microtransplantation
procedure leads to incorporation into the oocyte membrane of
receptors still embedded in their native membrane, other factors
may affect the EC50 for ACh in this preparation. Membrane lipids
modulate ACh-evoked responses in dystrophic mouse myotubes
(31) and induce loss of function of AChR reconstituted in mam-
malian cells (32). Differences in membrane lipid composition
could also account for the reduced stability of cell-attached
patches experienced when recording from myotubes derived from
ALS patients.
It has been reported recently that riluzole can induce a delay
in the progression of the disease and reduce extensive use of
artificial ventilation in ALS patients (2). Riluzole blocks voltage-
gated sodium channels plus a variety of other channels (33–35)
and inhibits ACh currents in transfected cell lines at very high
concentrations (17). However, to date there have been no studies
of AChRs in ALS muscles (2). In this study we used two different
technical approaches, both of which showed that riluzole, at
clinically relevant doses, can block the ACh-evoked currents in
ALS patients as well as in denervated patients. Because ongoing
myogenesis has been reported in muscle biopsies of ALS or
traumatically denervated patients (36), innervation of newly
formed muscle fibers likely proceeds alongside reinnervation of
old fibers by surviving motor neurons in ALS patients. The ac-
tivity of AChRs plays a role in both processes. Whether or not
riluzole interferes with this process becomes an interesting open
question. We also tested two other drugs, galantamine and Epo,
which have been recently suggested as alternative therapeutic
drugs for ALS (21, 23). Our voltage-dependent block of IACh by
galantamine is in good agreement with previous findings on
AChRs reconstituted in HEK cells (22), whereas Epo does not
affect these currents. Responses induced by low concentrations
of galantamine likely remained below detection threshold due to
the low potency of this agonist in our system. The reported
therapeutic action of these drugs may not be related to their
effect on postsynaptic muscle AChRs but to their action on
presynaptic mechanisms such as glutamate release or neuronal
cholinergic activation (21, 37, 38) that we cannot explore with
our preparations. In conclusion, the present work helps to un-
derstand the mechanisms underlying ALS pathology by (i) pro-
viding simple but powerful techniques to study the muscle
physiopathology of ALS using small amounts of tissue obtained
through muscle biopsies; and (ii) suggesting that muscle AChRs
could be a target for new drugs paving the way for developing
alternative strategies toward the medical treatment of ALS (39).
Materials and Methods
Patients. We obtained muscle specimens from 19 ALS patients (P1–19, Table
S1) and 9 control patients with muscle denervation due to other causes (P20–
28, Table S1). All patients were recruited and examined by the neurologists
(directed by M.I.) at the Neuromuscular Disease Unit of the Policlinico
Umberto I, Sapienza University, Rome. SI Materials and Methods provides
further details. Informed consent to use part of the biopsy material for our
experiments was obtained from all patients. The human subjects ethical
committee of Sapienza University approved the selection process and
surgical procedures.
Membrane Preparation, Injection Procedures, and Electrophysiological Record-
ings from Oocytes. Human muscle specimens (10–100 mg) were frozen in
liquid nitrogen immediately after biopsy and stored at −80 °C. Membranes
were prepared as previously detailed (40). Preparation of Xenopus laevis
oocytes and injection procedures were as detailed elsewhere (40, 41).
Membrane currents were recorded from voltage-clamped oocytes 24–48 h
after injection using two microelectrodes filled with 3 M KCl. The oocytes
were placed in a recording chamber (volume, 0.1 mL) and perfused contin-
uously, 9–10 mL/min, with oocyte Ringer’s solution (OR) at room
Fig. 5. ACh-evoked currents in myotubes. (A) Typical whole-cell current
responses evoked by ACh (100 μM; −60 mV) alone (C) or together with
riluzole (R; 0.5 μM, 30-s pretreatment) in myotubes derived from a de-
nervated patient (Left, P28) and an ALS patient (Right, P19). (B) Dispersion
plot of control ACh-evoked current density in all myotubes tested. Bars
represent mean ± 95% confidence interval of values. (C) ACh-evoked unitary
channel openings (upward) in myotubes from a denervated patient (P27,
Left) and an ALS patient (P18, Right). Channel conductances were 33.5 pS
(Left) and 30 pS (Right). The distribution of channel open duration in these
recordings was best fitted with the sum (continuous lines) of two expo-
nential components (dotted lines), with time constants 3.2 ms (44%) and
16.6 ms (56%) (Left); 1.6 ms (38%) and 16.2 ms (62%) (Right).
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temperature (20–22 °C). Unless otherwise specified, the oocytes were volt-
age clamped at −60 mV. To construct current–voltage (I–V) relationships, the
membrane potential was stepped to the desired values 2–4 min before ap-
plying ACh. To determine the reversal of IACh, I–V relationships were fitted
with a second order polynomial using pClamp 10 software. Decreases in IACh
during repetitive ACh applications (100 μM for 5 s at 40-s intervals) were
quantified by expressing the peak amplitude of the 10th response as a per-
centage of the peak amplitude of the first. Rapid IACh desensitization was
measured by fitting ACh currents with a first order exponential function and
calculating the time constant (τdecay).
The IC50 of riluzole and the ACh concentration producing EC50 were es-
timated by fitting the data to Hill equations, using least-square routines as
previously described (41).
Galantamine hydrobromide (Tocris), riluzole hydrochloride (Sigma or
Tocris), human Epo, α-bungarotoxin, d-tubocurarine, ACh, and nicotine were
dissolved in OR just before use. Where not indicated, drugs were purchased
from Sigma. Data were analyzed using Sigma Plot software and are given as
means ± SEM; datasets are considered statistically different when P < 0.05.
(ANOVA test). SI Materials and Methods provides further information.
Cell Culture and Patch-Clamp Recordings in Myotubes. Human myotubes were
obtained from satellite cells derived from human muscle needle biopsies
obtained as above, using previously reported procedures for culture (16) and
staining (42), as detailed in SI Materials and Methods. Cultures were main-
tained in a humidified incubator with 5% CO2, at 37 °C. All of the media
were purchased from Gibco/Invitrogen, except for the epidermal growth
factor (Sigma). Patch-clamp recordings were performed using borosilicate
glass patch pipettes (3–5 MΩ tip resistance, Sylgard coated for single-channel
recordings) connected to an Axopatch 200B amplifier (Molecular Devices)
driven by pCLAMP9 software (Molecular Devices). In whole-cell experiments,
cell capacitance and patch series resistance (5–15 MΩ) were estimated from
slow transient compensations, with a series resistance compensation of 80–
95%. Cells were voltage clamped at a holding potential (HP) of -60mV (unless
otherwise indicated) and continuously superfused using a gravity-driven
perfusion system with independent tubes for standard and agonist-contain-
ing solutions positioned 50–100 μm from the patched cell using a fast ex-
changer system (RSC-200; BioLogique). Normal extracellular solution (NES)
contained (mM): NaCl 140, KCl 2.8, CaCl2 2, MgCl2 2, Glucose 10, Hepes/NaOH
10, pH 7.3; intracellular solution contained (mM), CsCl 140, MgCl2 2, BAPTA 5,
Hepes/CsOH 10, Mg-ATP 2, pH 7.3. For cell-attached recordings, an extracel-
lular solution with swapped concentrations of NaCl and KCl was used.
Single-channel data were recorded sampling at 25 kHz. Cells were bathed
in a solution containing (mM): KCl 140, Na 2.8, CaCl2 2, MgCl2 2, Glucose 10,
Hepes/NaOH 10, pH 7.3, whereas pipettes were filled with NES. Analysis was
performed after Gaussian filtering at 2.5 kHz with a 50% threshold criterion
using pClamp9 software.
Data are given as means ± SEM. Two datasets were considered statistically
different when P < 0.05 (ANOVA test).
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